參考文獻(xiàn)/References:
[1] Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2] Bruna P,Bruna M, Enrique B.Human papillomavirus and genome instability: from productive infection to cancer[J].Clinics(Sao Paulo),2018,73(suppl 1):e539s.
[3] Manini I,Montomoli E.Epidemiology and prevention of Human Papillomavirus[J].Ann Ig,2018,30(4 Supple 1):28-32.
[4] Bernard H U, Burk R D, Chen Z, et al.Classification of papillomaviruses(PVs)based on 189 PV types and proposal of taxonomic amendments[J].Virology,2010,401(1):70-79.
[5] McLaughlin-Drubin M E, Münger K.Oncogenic activities of human papillomaviruses[J].Virus Res,2009,143(2):195-208.
[6] 中華醫(yī)學(xué)會婦產(chǎn)科分會感染協(xié)作組.女性下生殖道人乳頭瘤病毒感染診治專家共識[J].中國實(shí)用婦科與產(chǎn)科雜志,2015,31(10):894-894.
[7] Skye M,Dina S,Julia M L, et al.Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-Istudy[J]. Vaccine, 2018, 36(29): 4311-4316.
[8] 李曉琳,萬曉潔,鄭飛云,等.宮頸上皮內(nèi)瘤變Ⅱ/Ⅲ級及宮頸癌中人乳頭瘤病毒基因型分布的比較[J].實(shí)用醫(yī)學(xué)雜志,2016,32(15):2474-2497.
[9] 呂攀攀,徐小勤,王強(qiáng),等.14 種高危型人乳頭瘤病毒檢測對宮頸細(xì)胞病變的篩查作用[J].中國婦產(chǎn)科臨床雜志,2020, 21(1):6-9.
[10] 賀國麗,吳秀榮,鄭碧娟.宮頸癌與癌前病變中高危人乳頭瘤病毒型別特征及差異分析[J].實(shí)用婦產(chǎn)科雜志,2016,32(6):459-461.
[11] Canfell K.Towards the global elimination of cervical cancer[J].Papillomavirus Res,2019,8:100170.
[12] 李 雷,郎景和.人乳頭瘤病毒疫苗研究進(jìn)展[J].中國實(shí)用婦科與產(chǎn)科雜志.2017, 33(7):769-772.
[13] De Sanjose S,Quint W G,Alemany L,et al.Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. Lancet Oncol,2010,11(11):1048-1056.
[14] De Sanjose S,Quint W G,Alemany L,et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. Lancet Oncol,2010,11(11): 1048-1056.
[15] 鄧六六,吳莉英,潘中亞,等.22234 例子宮頸高危型 HPV 感染及亞型分布研究[J]. 實(shí)用婦產(chǎn)科雜志,2020,36(2):128-131.
相似文獻(xiàn)/References:
[1]黃 勉 林 珺 沈 張 金 瓊 陶 紅 吳三山 劉禹利.PAX1基因甲基化用于子宮頸癌臨床應(yīng)用價值探討[J].福建醫(yī)藥雜志,2020,42(03):3.
HUANG Mian,LIN Jun,SHEN Zhang,et al.Clinical application value of methylated PAX1 gene in cervical cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(01):3.
[2]林智平 王 英 王蘭蘭 羅益平.老年宮頸癌患者外周血S100A8水平和術(shù)后認(rèn)知功能障礙發(fā)生的關(guān)系[J].福建醫(yī)藥雜志,2020,42(05):5.
LIN Zhiping,WANG Ying,WANG Lanlan,et al.Relationship between peripheral blood S100A8 level and postoperative cognitive dysfunction in elderly patients with cervical cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(01):5.
[3]何海新,盧永偉,林翠波,等.PTEN抑制劑逆轉(zhuǎn)靶向microRNA-24抑制宮頸癌發(fā)生、發(fā)展的機(jī)制探索[J].福建醫(yī)藥雜志,2024,46(07):69.[doi:10.20148/j.fmj.2024.07.022]
HE Haixin,LU Yongwei,LIN Cuibo,et al.Mechanism exploration of reverse targeting of microRNA-24 by PTEN inhibitors to inhibit the occurrence and development of cervical cancer[J].FUJIAN MEDICAL JOURNAL,2024,46(01):69.[doi:10.20148/j.fmj.2024.07.022]